PFE240809P30500
- 1.65
- -0.01-0.60%
Pfizer Newsroom
Pfizer Analyst Ratings
Daiwa Securities Upgrades Pfizer to Outperform From Neutral, Adjusts Price Target to $34 From $28
Truist Financial Maintains Pfizer(PFE.US) With Buy Rating
Moderna Stock Trading Lower On Dismal Guidance, Analysts Cuts Price Targets Noting Competitive Pressure From GSK, Pfizer
Argus Research Maintains Pfizer(PFE.US) With Hold Rating
Pfizer Price Target Maintained With a $45.00/Share by Cantor Fitzgerald
Pfizer Price Target Raised to $31.00/Share From $30.00 by UBS
Pfizer Analyst Ratings
DZ BANK AG Maintains Pfizer(PFE.US) With Buy Rating
BofA Securities Maintains Pfizer(PFE.US) With Hold Rating
A Quick Look at Today's Ratings for Pfizer(PFE.US), With a Forecast Between $32 to $45
Cantor Fitzgerald Sticks to Its Buy Rating for Pfizer (PFE)
Truist Financial Keeps Their Buy Rating on Pfizer (PFE)
Morgan Stanley Raises Price Target on Pfizer to $31 From $29, Keeps Equalweight Rating
Pfizer Hold Rating Maintained Amid Growth Challenges and Valuation Concerns
Barclays Remains a Hold on Pfizer (PFE)
Jefferies Adjusts Price Target on Pfizer to $35 From $34, Keeps Buy Rating
J.P. Morgan Sticks to Its Hold Rating for Pfizer (PFE)
Buy Rating Affirmed: Sangamo's Hemophilia A Gene Therapy Poised for Success With Pfizer Partnership
Eli Lilly, Novo Are Weight-Loss Winners. Rivals Won't Be an Issue for Years: Analyst. -- Barrons.com